Zoetis Inc. and Alnylam Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis

A Tale of Two Companies: Zoetis Inc. vs. Alnylam Pharmaceuticals, Inc.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. This analysis delves into the gross profit trends of Zoetis Inc. and Alnylam Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Zoetis Inc. consistently outperformed Alnylam, with gross profits peaking at approximately $5.8 billion in 2023, a 90% increase from 2014. In contrast, Alnylam Pharmaceuticals saw a remarkable growth trajectory, with gross profits surging by over 2,900%, reaching $1.5 billion in 2023. This stark contrast highlights Zoetis's steady dominance and Alnylam's rapid ascent in the industry. As Zoetis continues to leverage its established market presence, Alnylam's innovative approach is reshaping its financial landscape, making it a company to watch in the coming years.

Key Insights

• Zoetis's gross profit grew by 90% over the decade.
• Alnylam's gross profit increased by over 2,900% from 2014 to 2023.